Streetbeat News

Stock Prices

ABBV

AbbVie's stock has been upgraded by Barclays from Equal-Weight to Overweight, with a price target increase from $160 to $170. Morgan Stanley also raised its price target on the stock from $193 to $196.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 2:29 pm

AMZN

PINS

Pinterest Inc (PINS) is set to report its Q3 2023 earnings, with analysts expecting $0.20 in EPS and $743.4 million in revenue. The company's international monetization strategies are proving successful, with significant growth potential in Australia, Japan, and Latin America. The partnership with Amazon.com Inc (AMZN) and recovering ad spends are expected to boost the stock. However, maintaining and increasing ARPU in a competitive market and continued monetization from new markets could impact the business and stock. PINS stock is up 11.3% over the past year, and the latest price target is $33/share, representing a possible 34.8% upside.

Portfolio Pulse from Surbhi Jain

October 30, 2023 | 2:28 pm

F

Ford Motor Co's shares hit a new 52-week low, trading lower by 2.7% to $9.70. The downward momentum follows mixed Q3 results, withdrawal of 2023 guidance, and postponement of $12 billion planned for EV investment. Ford also reached a tentative agreement with UAW to resolve a strike, entailing a 25% wage increase for all employees and additional benefits. The company's Q3 revenue was $44 billion, an 11% increase YoY, but fell short of earnings expectations.

Portfolio Pulse from Henry Khederian

October 30, 2023 | 2:26 pm

DQ

DAQO New Energy reported its Q3 financial results, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 2:22 pm

JKS

JinkoSolar Holding reported better-than-expected Q3 financial results and issued Q4 guidance. The company also disclosed that its N-Type Monocrystaline Silicon Solar Cell set a new record.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 2:20 pm

VYNE

Vyne Therapeutics Inc. (NASDAQ:VYNE) shares are trading higher after the company announced an $88 million private placement and positive data from its Phase 1b trial. The company also revealed new preclinical data showing the positive effect of its oral small molecule BD2-selective BET inhibitor, VYN202, in preclinical models of psoriasis and rheumatoid arthritis. The net proceeds from the financing are expected to fund the company through critical milestones, including the advancement of VYN201 into a Phase 2b clinical trial in vitiligo and Phase 1 trials for VYN202.

Portfolio Pulse from Erica Kollmann

October 30, 2023 | 2:19 pm

FMC

FMC Corporation is expected to release its Q3 financial results on Oct. 30, 2023. Analysts predict a decrease in earnings per share and revenue compared to the previous year. The company has also revised its Q3 and FY23 outlook downwards. FMC shares gained 0.8% to close at $56.88 on Friday. Several analysts have recently revised their ratings and price targets for FMC, with most downgrading the stock or maintaining a neutral stance.

Portfolio Pulse from Lisa Levin

October 30, 2023 | 2:18 pm

ALZN

Alzamend Neuro Inc's shares have dropped by 31.2% after the company announced a one-for-fifteen reverse stock split. The move is aimed at regaining compliance with Nasdaq's Minimum Bid Price Requirement of $1.00 per share. The split will affect all existing shares and shares available for issuance under equity incentive plans, but will not change the par value of the common stock.

Portfolio Pulse from Henry Khederian

October 30, 2023 | 2:16 pm

CMG

A large bearish position has been taken on Chipotle Mexican Grill (NYSE:CMG), as observed in the publicly available options history. The sentiment among these big-money traders is split between 23% bullish and 76% bearish. The whales have been targeting a price range from $1600.0 to $1985.0 for Chipotle over the last 3 months. Despite this, several financial institutions maintain a positive rating on CMG, with price targets ranging from $2250 to $2330.

Portfolio Pulse from Benzinga Insights

October 30, 2023 | 2:16 pm

BA

A significant investor has taken a bearish stance on Boeing (NYSE:BA), with 71% of recent trades being bearish and 28% bullish. The trades include 12 puts and 2 calls, with a total amount of $1,391,344 and $6,146,150 respectively. The price target for Boeing over the last 3 months has been between $145.0 to $250.0. The current price of BA is up 0.76% at $181.06. Analysts from Citigroup, Morgan Stanley, UBS, RBC Capital, and Wells Fargo have maintained their ratings on Boeing, with price targets ranging from $200 to $275.

Portfolio Pulse from Benzinga Insights

October 30, 2023 | 2:16 pm